Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an allergy pill mend hearts after an attack?

NCT ID NCT06548204

Disease control Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This trial tests whether fexofenadine, a common allergy medication, can help the heart heal better after a severe type of heart attack called STEMI. Participants will receive either fexofenadine or a placebo for six months, alongside standard care, after undergoing a procedure to open the blocked artery. The study uses MRI scans to measure heart muscle scarring and function, aiming to see if the drug reduces damage and improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fexofenadine hydrochloride
What this could lead to
If effective, fexofenadine could become a simple, widely available add-on treatment to reduce heart muscle scarring and improve recovery after a heart attack.
What could go wrong
This is an early-stage trial with a modest number of participants. The drug may not reduce scarring, and its benefits might not extend beyond the specific heart attack population studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages above 18; * Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He/she or his/her legal representative shall provide written informed consent before participating in the clinical trial. * Meet the diagnostic criteria for STEMI, the diagnostic criteria includes: 1. Clinical symptoms: ischemic chest pain lasting for over 30 minites; 2. Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit); 3. ST segment elevation: new ST segment elevation in two or more adjacent leads on the ECG; * Emergency coronary angiography and revascularization should be performed; * Ultrasonic cardiogram indicates regional wall motion abnormality, and transthoracic echocardiography shows LVEF ≤ 50% within 72 hours after revascularization. Exclusion Criteria: * Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors; * Previously suffered from myocardial infarction or received coronary artery bypass grafting; * Patients with concomitant cardiomyopathy or valve disease; * History of severe renal failure, estimated glomerular filtration rate (eGFR) \< 30ml/min; * History of severe liver dysfunction; * Concurrent severe infections, or liver/gallbladder obstruction, or history of malignant tumors; * Currently receiving immunosuppressive therapy; * Pregnant or potentially pregnant and breastfeeding women; * Contraindications for fexofenadine hydrochloride or cardiac magnetic resonance examinations; * Without obtaining written informed consent. * Patients with hemodynamic instability.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST-segment elevation myocardial infarction (stemi) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST-segment elevation myocardial infarction (stemi)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The 2nd Affiliated Hopital of Zhejiang University, School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.